Citadel Advisors’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-36,500
| Closed | -$3.89M | – | 14200 |
|
|
2025
Q3 | $3.89M | Sell |
36,500
-174,600
| -83% | -$18.2M | ﹤0.01% | 4811 |
|
|
2025
Q2 | $20M | Sell |
211,100
-27,400
| -11% | -$2.03M | ﹤0.01% | 2133 |
|
|
2025
Q1 | $15.1M | Buy |
238,500
+111,800
| +88% | +$6.69M | ﹤0.01% | 2351 |
|
|
2024
Q4 | $5.88M | Sell |
126,700
-136,700
| -52% | -$5.13M | ﹤0.01% | 3703 |
|
|
2024
Q3 | $7.58M | Buy |
263,400
+104,500
| +66% | +$2.57M | ﹤0.01% | 3326 |
|
|
2024
Q2 | $2.3M | Buy |
158,900
+123,100
| +344% | +$1.8M | ﹤0.01% | 5060 |
|
|
2024
Q1 | $576K | Sell |
35,800
-3,600
| -9% | -$62.3K | ﹤0.01% | 8073 |
|
|
2023
Q4 | $783K | Buy |
39,400
+100
| +0.3% | +$1.48K | ﹤0.01% | 7178 |
|
|
2023
Q3 | $641K | Sell |
39,300
-5,900
| -13% | -$114K | ﹤0.01% | 7529 |
|
|
2023
Q2 | $956K | Buy |
45,200
+22,500
| +99% | +$480K | ﹤0.01% | 6553 |
|
|
2023
Q1 | $456K | Sell |
22,700
-16,700
| -42% | -$361K | ﹤0.01% | 8501 |
|
|
2022
Q4 | $1.03M | Buy |
+39,400
| New | +$525K | ﹤0.01% | 6761 |
|
|
2022
Q1 | – | Sell |
-12,700
| Closed | -$85K | – | 14668 |
|
|
2021
Q4 | $85K | Buy |
+12,700
| New | +$64.9K | ﹤0.01% | 12880 |
|
|
2021
Q2 | – | Sell |
-11,800
| Closed | -$99K | – | 14512 |
|
|
2021
Q1 | $99K | Sell |
11,800
-3,000
| -20% | -$24.9K | ﹤0.01% | 12486 |
|
|
2020
Q4 | $104K | Buy |
+14,800
| New | +$100K | ﹤0.01% | 10200 |
|
Other funds holding VRNA
Citadel Advisors's VRNA Position: Q4 2025 in Review
Citadel Advisors sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 461,869 shares — an estimated $49.3M sold.
Citadel Advisors first reported a position in VRNA in Q1 2019 and held it in 16 quarters. The position peaked at $132M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- Citadel Advisors reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 461,869 Verona Pharma shares in Q4 2025, an estimated $49.3M.
- Citadel Advisors first reported a position in Verona Pharma in Q1 2019 and held it in 16 quarters.
- Citadel Advisors's Verona Pharma position peaked at $132M in Q2 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.